NASDAQ:PRE Prenetics Global (PRE) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free PRE Stock Alerts $5.23 -0.10 (-1.88%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$5.16▼$5.6650-Day Range$2.90▼$5.6752-Week Range$2.85▼$15.90Volume22,541 shsAverage Volume101,885 shsMarket Capitalization$47.80 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Prenetics Global alerts: Email Address Prenetics Global MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.1% Upside$9.00 Price TargetShort InterestHealthy0.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.15 out of 5 starsMedical Sector4129th out of 5,424 stocksHolding & Other Investment Offices Industry25th out of 60 stocks 3.5 Analyst's Opinion Consensus RatingPrenetics Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrenetics Global has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.42% of the float of Prenetics Global has been sold short.Short Interest Ratio / Days to CoverPrenetics Global has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prenetics Global has recently increased by 148.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrenetics Global does not currently pay a dividend.Dividend GrowthPrenetics Global does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRE. Previous Next 0.6 News and Social Media Coverage Search Interest10 people have searched for PRE on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prenetics Global insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Prenetics Global is held by insiders.Percentage Held by InstitutionsOnly 25.01% of the stock of Prenetics Global is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Prenetics Global is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prenetics Global is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrenetics Global has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Prenetics Global Stock (NASDAQ:PRE)Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.Read More PRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRE Stock News HeadlinesApril 26, 2024 | americanbankingnews.comPrenetics Global (NASDAQ:PRE) Trading 3.8% Higher April 6, 2024 | benzinga.comPrenetics Global Stock (NASDAQ:PRE), Analyst Ratings, Price Targets, PredictionsMay 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 3, 2024 | baystreet.caPrenetics Flat on Financial ResultsApril 1, 2024 | finanznachrichten.dePrenetics Global Limited: Prenetics Announces Fourth Quarter and Full Year 2023 Financial ResultsApril 1, 2024 | benzinga.comPrenetics Global: Q4 Earnings InsightsApril 1, 2024 | investorplace.comPRE Stock Earnings: Prenetics Global Beats EPS, Misses Revenue for Q4 2023April 1, 2024 | globenewswire.comPrenetics Announces Fourth Quarter and Full Year 2023 Financial ResultsMay 4, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 9, 2024 | finance.yahoo.comPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space StationFebruary 9, 2024 | globenewswire.comPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space StationJanuary 17, 2024 | msn.comPrenetics Global files to sell 1.48M Class A shares for holdersDecember 18, 2023 | investing.comPrenetics Global (PRE) Earnings Dates & ReportsDecember 17, 2023 | seekingalpha.comPRENW Prenetics Global Limited WT EXP 051827November 20, 2023 | benzinga.comPrenetics Global Stock (NASDAQ:PRE) Insider TradesNovember 20, 2023 | msn.comPrenetics Global GAAP EPS of -$0.08, revenue of $4.86MNovember 20, 2023 | benzinga.comPrenetics Global: Q3 Earnings InsightsNovember 20, 2023 | finance.yahoo.comPrenetics Announces Third Quarter 2023 Financial ResultsNovember 11, 2023 | finance.yahoo.comPrenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?November 5, 2023 | morningstar.comPrenetics Global Ltd Class A PRENovember 1, 2023 | msn.comPrenetics Global announces reverse stock splitNovember 1, 2023 | finance.yahoo.comPrenetics Global Limited Announces Reverse Stock SplitOctober 30, 2023 | money.usnews.comPrenetics Global Limited - Ordinary Shares - Class AOctober 3, 2023 | finance.yahoo.comGenetic Genealogy Market | Direct-To-Customer Segment Registered The Highest Growth - Here's WhySeptember 15, 2023 | finanznachrichten.dePrenetics Global Limited: Prenetics Announces Second Quarter 2023 Financial ResultsSeptember 15, 2023 | finance.yahoo.comPrenetics Announces Second Quarter 2023 Financial ResultsSeptember 10, 2023 | finance.yahoo.comPRE - Prenetics Global LimitedSee More Headlines Receive PRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/03/2024Next Earnings (Estimated)6/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:PRE CUSIPN/A CIK1876431 Webwww.prenetics.com Phone852-2210-9588FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+72.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.7985) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,720,000.00 Net Margins-193.60% Pretax Margin-260.63% Return on Equity-11.15% Return on Assets-9.03% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio2.29 Sales & Book Value Annual Sales$21.74 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value$23.00 per share Price / Book0.23Miscellaneous Outstanding Shares9,140,000Free Float8,424,000Market Cap$47.80 million OptionableNot Optionable Beta-0.28 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Sheng Wu Yeung (Age 45)Co-Founder, Chairperson & CEO Dr. Chi Hung Tzang Ph.D. (Age 49)Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board Mr. Hoi Chun Lo (Age 39)Chief Financial Officer Dr. Yung Ho Wong DPHIL (Age 42)Chief Technology Officer Ms. Samantha KwokChief of Staff to Group CEO & Vice President, People & OperationsDr. Senthil Sundaram M.D. (Age 50)Chief Clinical Officer Mr. Joel NeohChief Consumer Officer & Chief Executive Officer for CircleDNAMr. Walt LingChief Executive Officer of ACT GenomicsMore ExecutivesKey CompetitorsCERo TherapeuticsNASDAQ:CEROFuture Health ESGNASDAQ:FHLTARYA Sciences Acquisition Corp IVNASDAQ:ARYDJupiter WellnessNASDAQ:JUPWQuince TherapeuticsNASDAQ:QNCXView All CompetitorsInstitutional OwnershipNomura Holdings Inc.Bought 113,288 shares on 3/27/2024Ownership: 2.122%Prudential PLCSold 9,591,997 shares on 2/14/2024Ownership: 7.493%Aspex Management HK LtdSold 4,846,100 shares on 2/14/2024Ownership: 3.787%View All Institutional Transactions PRE Stock Analysis - Frequently Asked Questions Should I buy or sell Prenetics Global stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prenetics Global in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRE shares. View PRE analyst ratings or view top-rated stocks. What is Prenetics Global's stock price target for 2024? 1 Wall Street research analysts have issued twelve-month price targets for Prenetics Global's shares. Their PRE share price targets range from $9.00 to $9.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for PRE or view top-rated stocks among Wall Street analysts. How have PRE shares performed in 2024? Prenetics Global's stock was trading at $5.91 on January 1st, 2024. Since then, PRE shares have decreased by 11.5% and is now trading at $5.23. View the best growth stocks for 2024 here. Are investors shorting Prenetics Global? Prenetics Global saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 31,800 shares, an increase of 148.4% from the March 31st total of 12,800 shares. Based on an average daily trading volume, of 123,100 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.4% of the shares of the stock are sold short. View Prenetics Global's Short Interest. When is Prenetics Global's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024. View our PRE earnings forecast. How were Prenetics Global's earnings last quarter? Prenetics Global Limited (NASDAQ:PRE) released its earnings results on Monday, April, 1st. The company reported ($0.52) earnings per share for the quarter. The company earned $5.43 million during the quarter. Prenetics Global had a negative net margin of 193.60% and a negative trailing twelve-month return on equity of 11.15%. When did Prenetics Global's stock split? Prenetics Global's stock reverse split on the morning of Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Prenetics Global? Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRE) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prenetics Global Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.